Achieving low defibrillation thresholds at implant: Pharmacological influences, RV coil polarity and position, SVC coil usage and positioning, pulse width settings, and the azygous vein

Fundamental and Clinical Pharmacology

Volumn 24, Issue 5, 2010, Pages 561-573

  Kroll, Mark W ^a   Schwab, Joerg O ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

defibrillation; DFT; ICD; threshold

Indexed keywords

AMIODARONE; ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; AZIMILIDE; BUPIVACAINE; CARVEDILOL; CLOFILIUM; COCAINE; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; ENCAINIDE; FENTANYL; FLECAINIDE; HALOTHANE; IBUTILIDE; ISOFLURANE; LIDOCAINE; METOPROLOL; MEXILETINE; MORACIZINE; POTASSIUM CHANNEL HERG; PROCAINAMIDE; PROPOFOL; SILDENAFIL; SOTALOL; UNINDEXED DRUG; VENLAFAXINE; VERAPAMIL;

ADRENERGIC ACTIVITY; BRACHIOCEPHALIC VEIN; COCAINE DEPENDENCE; DEFIBRILLATION; DEFIBRILLATION THRESHOLD; DRUG WITHDRAWAL; ELECTROPORATION; HEART ATRIUM FIBRILLATION; HEART MUSCLE REFRACTORY PERIOD; HEART RIGHT ATRIUM; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE OUTFLOW TRACT; HEART VENTRICLE FIBRILLATION; HUMAN; IMPEDANCE; IMPLANT; PRIORITY JOURNAL; PUERPERAL DEPRESSION; PULSE WAVE; QT PROLONGATION; REVIEW; SUPERIOR CAVA VEIN;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; TACHYCARDIA, VENTRICULAR; VENA CAVA, SUPERIOR; VENTRICULAR FIBRILLATION;

EID: 77956946087     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00848.x     Document Type: Review

References (137)

1. Anderson K.P. Sudden cardiac death unresponsive to implantable defibrillator therapy: an urgent target for clinicians, industry and government. J. Interv. Card. Electrophysiol. (2005) 14 71 78.
2. Mitchell L.B., Pineda E.A., Titus J.L., Bartosch P.M., Benditt D.G. Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation. J. Am. Coll. Cardiol. (2002) 39 1323 1328.
3. Pires L.A., Hull M.L., Nino C.L., May L.M., Ganji J.R. Sudden death in recipients of transvenous implantable cardioverter defibrillator systems: terminal events, predictors, and potential mechanisms. J. Cardiovasc. Electrophysiol. (1999) 10 1049 1056.
4. Gold M.R., Kroll M.W., Ellenbogen K.A. Defibrillation testing at ICD implantation: are we asking the wrong question? Pacing Clin. Electrophysiol. (2009) 32 567 569.
5. Viskin S., Rosso R. The top 10 reasons to avoid defibrillation threshold testing during ICD implantation. Heart Rhythm (2008) 5 391 393.
6. Birnie D., Tung S., Simpson C. et al. Complications associated with defibrillation threshold testing: the Canadian experience. Heart Rhythm (2008) 5 387 390.
7. Moss A.J., Greenberg H., Case R.B. et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation (2004) 110 3760 3765.
8. Poole J.E., Johnson G.W., Hellkamp A.S. et al. Prognostic importance of defibrillator shocks in patients with heart failure. N. Engl. J. Med. (2008) 359 1009 1017.
9. Tang W., Weil M.H., Sun S. et al. The effects of biphasic and conventional monophasic defibrillation on postresuscitation myocardial function. J. Am. Coll. Cardiol. (1999) 34 815 822. (Pubitemid 29436189)
10. Tokano T., Bach D., Chang J. et al. Effect of ventricular shock strength on cardiac hemodynamics. J. Cardiovasc. Electrophysiol. (1998) 9 791 797.
11. Xie J., Weil M.H., Sun S. et al. High-energy defibrillation increases the severity of postresuscitation myocardial dysfunction. Circulation (1997) 96 683 688.
12. Sweeney M.O., Sherfesee L., DeGroot P.J., Wathen M.S., Wilkoff B.L. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm (2010) 7 353 360.
13. Tereshchenko L.G., Faddis M.N., Fetics B.J., Zelik K.E., Efimov I.R., Berger R.D. Transient local injury current in right ventricular electrogram after implantable cardioverter-defibrillator shock predicts heart failure progression. J. Am. Coll. Cardiol. (2009) 54 822 828.
14. Stevens S.K., Haffajee C.I., Naccarelli G.V. et al. Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. Propafenone Defibrillation Threshold Investigators. J. Am. Coll. Cardiol. (1996) 28 418 422.
15. Deeb G.M., Hardesty R.L., Griffith B.P., Thompson M.E., Heilman M.S., Myerowitz R.L. The effects of cardiovascular drugs on the defibrillation threshold and the pathological effects on the heart using an automatic implantable defibrillator. Ann. Thorac. Surg. (1983) 35 361 366.
16. Echt D.S., Black J.N., Barbey J.T., Coxe D.R., Cato E. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation. Circulation (1989) 79 1106 1117.
17. Fan W., Gotoh M., Chen P.S. Effects of the pacing site, procainamide, and lead configuration on the relationship between the upper limit of vulnerability and the defibrillation threshold. Pacing Clin. Electrophysiol. (1995) 18 1279 1284.
18. Echt D.S., Gremillion S.T., Lee J.T. et al. Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillator devices. J. Cardiovasc. Electrophysiol. (1994) 5 752 760.
19. Murakawa Y., Inoue H., Kuo T.T. et al. Prolongation of intraventricular conduction time associated with fatal [correction of fetal] impairment of defibrillation efficiency during treatment with class I antiarrhythmic agents. J. Cardiovasc. Pharmacol. (1995) 25 194 199.
20. Murakawa Y., Sezaki K., Inoue H. et al. Shock-induced refractory period extension and pharmacologic modulation of defibrillation threshold. J. Cardiovasc. Pharmacol. (1994) 23 822 825.
21. Natale A., Jones D.L., Kleinstiver P.W., Kim Y.H., Wood G.K., Klein G.J. Effects of flecainide on defibrillation threshold in pigs. J. Cardiovasc. Pharmacol. (1993) 21 573 577. (Pubitemid 23095347)
22. Szabo T.S., Jones D.L., McQuinn R.L., Klein G.J. Flecainide acetate does not alter the energy requirements for direct ventricular defibrillation using sequential pulse defibrillation in pigs. J. Cardiovasc. Pharmacol. (1988) 12 377 383.
23. Hernandez R., Mann D.E., Breckinridge S., Williams G.R., Reiter M.J. Effects of flecainide on defibrillation thresholds in the anesthetized dog. J. Am. Coll. Cardiol. (1989) 14 777 781.
24. Allison J.S., Qin H., Dosdall D.J. et al. The transmural activation sequence in porcine and canine left ventricle is markedly different during long-duration ventricular fibrillation. J. Cardiovasc. Electrophysiol. (2007) 18 1306 1312.
25. Newton J.C., Smith W.M., Ideker R.E. Estimated global transmural distribution of activation rate and conduction block during porcine and canine ventricular fibrillation. Circ. Res. (2004) 94 836 842.
26. Pak H.N., Kim Y.H., Lim H.E. et al. Role of the posterior papillary muscle and purkinje potentials in the mechanism of ventricular fibrillation in open chest dogs and Swine: effects of catheter ablation. J. Cardiovasc. Electrophysiol. (2006) 17 777 783.
27. Sweeney R.J., Gill R.M., Steinberg M.I., Reid P.R. Effects of flecainide, encainide, and clofilium on ventricular refractory period extension by transcardiac shocks. Pacing Clin. Electrophysiol. (1996) 19 50 60.
28. Murakawa Y., Yamashita T., Kanese Y., Omata M. Do the effects of antiarrhythmic drugs on defibrillation efficacy vary among different shock waveforms? Pacing Clin. Electrophysiol. (1998) 21 1901 1908.
29. Sato S., Imagawa N. Effects of lidocaine and mexiletine on defibrillation energy requirements in animals treated with flecainide. Resuscitation (1998) 36 175 180.
30. Sato S., Tsuji M.H., Naito H. Mexiletine has no effect on defibrillation energy requirements in dogs. Pacing Clin. Electrophysiol. (1994) 17 (12 Pt 1) 2279 2284.
31. Jung W., Manz M., Pizzulli L., Pfeiffer D., Luderitz B. Effects of chronic amiodarone therapy on defibrillation threshold. Am. J. Cardiol. (1992) 70 1023 1027.
32. Crystal E., Ovsyshcher I.E., Wagshal A.B., Katz A., Ilia R. Mexiletine related chronic defibrillation threshold elevation: case report and review of the literature. Pacing Clin. Electrophysiol. (2002) 25 (4 Pt 1) 507 508.
33. Marinchak R.A., Friehling T.D., Kline R.A., Stohler J., Kowey P.R. Effect of antiarrhythmic drugs on defibrillation threshold: case report of an adverse effect of mexiletine and review of the literature. Pacing Clin. Electrophysiol. (1988) 11 7 12.
34. Hohnloser S.H., Dorian P., Roberts R. et al. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation (2006) 114 104 109.
35. Kalus J.S., White C.M., Caron M.F., Guertin D., McBride B.F., Kluger J. The impact of catecholamines on defibrillation threshold in patients with implanted cardioverter defibrillators. Pacing Clin. Electrophysiol. (2005) 28 1147 1156.
36. McBride B.F., White C.M., Kalus J.S. et al. The impact of carvedilol on the defibrillation threshold. Heart Lung (2008) 37 67 71.
37. Melichercik J., Goepfrich M., Breidenbach T., Von Hodenberg E. Rise of defibrillation energy requirement under carvedilol therapy. Pacing Clin. Electrophysiol. (2001) 24 (9 Pt 1) 1417 1419.
38. Simon R., Sturdivant J., Leman R., Wahrton J., Gold M. The effect of dofetilide on ventricular defibrillation thresholds. Pacing Clin. Electrophysiol. (2009) 32 24 28.
39. Efremidis M., Sideris A., Batra R. et al. Facilitating internal cardioversion of chronic atrial fibrillation with ibutilide - predictors of atrial defibrillation-threshold decrease. Med. Sci. Monit. (2004) 10 CR258 CR263.
40. Khoury D.S., Assar M.D., Sun H. Pharmacologic enhancement of atrial electrical defibrillation efficacy: role of ibutilide. J. Interv. Card. Electrophysiol. (1997) 1 291 298.
41. Carnes C.A., Mehdirad A.A. Effects of azimilide, acidemia, and the combination on defibrillation energy requirements. J. Cardiovasc. Pharmacol. (2000) 36 283 287.
42. Chevalier P., Dubieff A.D., Piqueras E. et al. The impact of acute myocardial ischemia on the ventricular defibrillation threshold during chronic oral azimilide therapy. J. Cardiovasc. Pharmacol. (2007) 50 629 632.
43. Qi X.Q., Newman D., Dorian P. Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation. J. Interv. Card. Electrophysiol. (1999) 3 61 67.
44. Nattel S., Liu L., St-Georges D. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc. Res. (1998) 37 627 635.
45. Stewart A.J., Allen J.D., Devine A.B., Adgey A.A. Effects of blockade of fast and slow inward current channels on ventricular fibrillation in the pig heart. Heart (1996) 76 513 519.
46. Jones D.L., Klein G.J., Guiraudon G.M., Yee R., Brown J.E., Sharma A.D. Effects of lidocaine and verapamil on defibrillation in humans. J. Electrocardiol. (1991) 24 299 305.
47. Anvari A., Mast F., Schmidinger H., Schuster E., Allessie M. Effects of lidocaine, ajmaline, and diltiazem on ventricular defibrillation energy requirements in isolated rabbit heart. J. Cardiovasc. Pharmacol. (1997) 29 429 435.
48. Cheek E.R., Ideker R.E., Fast V.G. Nonlinear changes of transmembrane potential during defibrillation shocks: role of Ca(2 +) current. Circ. Res. (2000) 87 453 459.
49. Daubert J.P., Sheu S.S. Mystery of biphasic defibrillation waveform efficacy is it calcium? J. Am. Coll. Cardiol. (2008) 52 836 838.
50. Fast V.G., Cheek E.R., Pollard A.E., Ideker R.E. Effects of electrical shocks on Cai2 + and Vm in myocyte cultures. Circ. Res. (2004) 94 1589 1597.
51. Mowrey K.A., Efimov I.R., Cheng Y. Membrane time constant during internal defibrillation strength shocks in intact heart: effects of Na(+) and Ca(2 +) channel blockers. J. Cardiovasc. Electrophysiol. (2009) 20 85 92.
52. Pelosi F. Jr., Oral H., Kim M.H. et al. Effect of chronic amiodarone therapy on defibrillation energy requirements in humans. J. Cardiovasc. Electrophysiol. (2000) 11 736 740.
53. Russo A.M., Sauer W., Gerstenfeld E.P. et al. Defibrillation threshold testing: is it really necessary at the time of implantable cardioverter- defibrillator insertion? Heart Rhythm (2005) 2 456 461.
54. Russo A.M., Verdino R., Schorr C. et al. Effect of long-term amiodarone on the defibrillation threshold: Potential for serious adverse effects. Pacing Clin. Electrophysiol. (2001) 24 578A.
55. Kowey P., Singh B. Dronedarone in patients with implantable defibrillators. Heart Rhythm (2004) abstract.
56. Dorian P., Newman D., Sheahan R., Tang A., Green M., Mitchell J. d-Sotalol decreases defibrillation energy requirements in humans: a novel indication for drug therapy. J. Cardiovasc. Electrophysiol. (1996) 7 952 961.
57. Weinbroum A.A., Glick A., Copperman Y., Yashar T., Rudick V., Flaishon R. Halothane, isoflurane, and fentanyl increase the minimally effective defibrillation threshold of an implantable cardioverter defibrillator: first report in humans. Anesth. Analg. (2002) 95 1147 1153, table of contents.
58. Moerman A., Herregods L., Tavernier R., Jordaens L., Struys M., Rolly G. Influence of anaesthesia on defibrillation threshold. Anaesthesia (1998) 53 1156 1159.
59. Peters R.W., Gilbert T.B., Johns-Walton S., Gold M.R. Lidocaine-related increase in defibrillation threshold. Anesth. Analg. (1997) 85 299 300.
60. Lipscomb K.J., Linker N.J., Fitzpatrick A.P. Subpectoral implantation of a cardioverter defibrillator under local anaesthesia. Heart (1998) 79 253 255.
61. Swerdlow C.D., Russo A.M., Degroot P.J. The dilemma of ICD implant testing. Pacing Clin. Electrophysiol. (2007) 30 675 700.
62. Shinlapawittayatorn K., Sungnoon R., Chattipakorn S., Chattipakorn N. Effects of sildenafil citrate on defibrillation efficacy. J. Cardiovasc. Electrophysiol. (2006) 17 292 295.
63. Chen J., Naseem R.H., Obel O., Joglar J.A. Habitual cocaine use is associated with high defibrillation threshold during ICD implantation. J. Cardiovasc. Electrophysiol. (2007) 18 722 725.
64. Karch S.B., Green G.S., Young S. Myocardial hypertrophy and coronary artery disease in male cocaine users. J. Forensic Sci. (1995) 40 591 595.
65. Liu T., Krummen D., Malhotra R., Feld G., Birgersdotter-Green U. Chronic methamphetamine use is correlated with high defibrillation threshold during ICD implantation. Heart Rhythm (2008) abstract.
66. Carnes C.A., Pickworth K.K., Votolato N.A., Raman S.V. Elevated defibrillation threshold with venlafaxine therapy. Pharmacotherapy (2004) 24 1095 1098.
67. Mainigi S.K., Callans D.J. How to manage the patient with a high defibrillation threshold. Heart Rhythm (2006) 3 492 495.
68. Yang F., Patterson R. Optimal transvenous coil position on active-can single-coil ICD defibrillation efficacy: a simulation study. Ann. Biomed. Eng. (2008) 36 1659 1667.
69. Chattipakorn N., Fotuhi P.C., Chattipakorn S.C., Ideker R.E. Three-dimensional mapping of earliest activation after near-threshold ventricular defibrillation shocks. J. Cardiovasc. Electrophysiol. (2003) 14 65 69.
70. Chattipakorn N., KenKnight B.H., Rogers J.M. et al. Locally propagated activation immediately after internal defibrillation. Circulation (1998) 97 1401 1410.
71. Efimov I.R., Cheng Y., Van Wagoner D.R., Mazgalev T., Tchou P.J. Virtual electrode-induced phase singularity: a basic mechanism of defibrillation failure. Circ. Res. (1998) 82 918 925.
72. Kroll M.W., Efimov I.R., Tchou P.J. Present understanding of shock polarity for internal defibrillation: the obvious and non-obvious clinical implications. Pacing Clin. Electrophysiol. (2006) 29 885 891.
73. Usui M., Walcott G.P., KenKnight B.H. et al. Influence of malpositioned transvenous leads on defibrillation efficacy with and without a subcutaneous array electrode. Pacing Clin. Electrophysiol. (1995) 18 2008 2016.
74. Crossley G.H., Boyce K., Roelke M. et al. A prospective randomized trial of defibrillation thresholds from the right ventricular outflow tract and the right ventricular apex. Pacing Clin. Electrophysiol. (2009) 32 166 171.
75. Mollerus M., Lipinski M., Munger T. A randomized comparison of defibrillation thresholds in the right ventricular outflow tract versus right ventricular apex. J. Interv. Card. Electrophysiol. (2008) 22 221 225.
76. Reynolds C., Nikolski V., Leman R. et al. A prospective, crossover comparison of defibrillation thresholds obtained in the right ventricular apex vs outflow tract. Heart Rhythm (2009) abstract.
77. Rodriguez-Diez G., Robledo R., Castro H., Ortiz M., Machuca J., DeHaro S. Comparation of Defibrillation Lead Implant in Apex Against Righ Ventricular Outflow Tract. Heart Rhythm (2008) abstract.
78. Schaerf R., Develle R., Shkurovich S. Comparison of ICD lead performance in three different sites in the right ventricle. Heart Rhythm (2008) abstract.
79. Ender S., Landers M., Ashar M., Gupta M. Comparison of defibrillation efficacy with ICD leads in the RVA vs RVOT. Heart Rhythm (2006) abstract.
80. Turakhia M., Prasad M., Olgin J. et al. Rates and severity of perforation from implantable cardioverter-defibrillator leads: a 4-year study. J. Interv. Card. Electrophysiol. (2009) 24 47 52.
81. Swerdlow C., Ahern T., Chen P.-S. Comparative reproducibility of defibrillation threshold and upper limit of vulnerability. Pacing Clin. Electrophysiol. (1996) 19 2103 2111.
82. Efimov I.R., Cheng Y., Yamanouchi Y., Tchou P.J. Direct evidence of the role of virtual electrode-induced phase singularity in success and failure of defibrillation. J. Cardiovasc. Electrophysiol. (2000) 11 861 868.
83. Strickberger S.A., Hummel J.D., Horwood L.E. et al. Effect of shock polarity on ventricular defibrillation threshold using a transvenous lead system. J. Am. Coll. Cardiol. (1994) 24 1069 1072.
84. Strickberger S.A., Daoud E., Goyal R. et al. Prospective randomized comparison of anodal monophasic shocks versus biphasic cathodal shocks on defibrillation energy requirements. Am. Heart J. (1996) 131 961 965.
85. Mowrey K.A., Cheng Y., Tchou P.J., Efimov R. Kinetics of defibrillation shock-induced response: design implications for the optimal defibrillation waveform. Europace (2002) 4 27 39.
86. Kroll M.W. A minimal model of the single capacitor biphasic defibrillation waveform. Pacing Clin. Electrophysiol. (1994) 17 (11 Pt 1) 1782 1792.
87. White J.B., Walcott G.P., Wayland J.L. Jr., Smith W.M., Ideker R.E. Predicting the relative efficacy of shock waveforms for transthoracic defibrillation in dogs. Ann. Emerg. Med. (1999) 34 309 320.
88. Walcott G.P., Walker R.G., Cates A.W., Krassowska W., Smith W.M., Ideker R.E. Choosing the optimal monophasic and biphasic waveforms for ventricular defibrillation. J. Cardiovasc. Electrophysiol. (1995) 6 737 750.
89. Swerdlow C., Fan W., Brewer J. Charge-burping theory correctly predicts optimal ratios of phase duration for biphasic defibrillation waveforms. Circulation (1996) 94 2278 2284.
90. Schauerte P.N., Ziegert K., Waldmann M. et al. Effect of biphasic shock duration on defibrillation threshold with different electrode configurations and phase 2 capacitances: prediction by upper-limit-of-vulnerability determination. Circulation (1999) 99 1516 1522.
91. Schauerte P., Schondube F.A., Grossmann M. et al. Influence of phase duration of biphasic waveforms on defibrillation energy requirements with a 70-microF capacitance. Circulation (1998) 97 2073 2078.
92. Schuder J., Stoeckle H., West J.A. Transthoracic ventricular defibrillation in the dog with truncated exponential stimuli. IEEE Trans. Biomed. Eng. (1971) 18 410 415.
93. Dillon S.M., Kwaku K.F. Progressive depolarization: a unified hypothesis for defibrillation and fibrillation induction by shocks. J. Cardiovasc. Electrophysiol. (1998) 9 529 552.
94. Chen P.-S., Wolf P.D., Ideker R.E. The mechanism of cardiac defibrillation: a different point of view. Circulation (1991) 84 913 919.
95. Cheng Y., Mowrey K.A., Van Wagoner D.R., Tchou P.J., Efimov I.R. Virtual electrode-induced reexcitation: A mechanism of defibrillation. Circ. Res. (1999) 85 1056 1066.
96. Hodgkin A. The subthreshold potentials in a crustacean nerve fiber. Proc. R. Soc. (1938) 126 87 121.
97. Kao C.Y., Hoffman B.F. Graded and decremental response in heart muscle fibers. Am. J. Physiol. (1958) 194 187 196.
98. Krassowska W., Cabo C., Knisley S.B., Ideker R.E. Propagation versus delayed activation during field stimulation of cardiac muscle. Pacing Clin. Electrophysiol. (1992) 15 197 210.
99. Jones J.L., Jones R.E. Improved defibrillator waveform safety factor with biphasic waveforms. Am. J. Physiol. (1983) 245 H60 H65.
100. Jones J.L., Jones R.E. Decreased defibrillator-induced dysfunction with biphasic rectangular waveforms. Am. J. Physiol. (1984) 247 (5 Pt 2) H792 H796.
101. Tovar O., Tung L. Electroporation of cardiac cell membranes with monophasic or biphasic rectangular pulses. Pacing Clin. Electrophysiol. (1991) 14 (11 Pt 2) 1887 1892.
102. Behrens S., Li C., Kirchhof P., Fabritz F.L., Franz M.R. Reduced arrhythmogenicity of biphasic versus monophasic T-wave shocks. Implications for defibrillation efficacy. Circulation (1996) 94 1974 1980.
103. Anderson C., Trayanova N., Skouibine K. Termination of spiral waves with biphasic shocks: role of virtual electrode polarization. J. Cardiovasc. Electrophysiol. (2000) 11 1386 1396.
104. Efimov I.R., Cheng Y.N., Biermann M., Van Wagoner D.R., Mazgalev T.N., Tchou P.J. Transmembrane voltage changes produced by real and virtual electrodes during monophasic defibrillation shock delivered by an implantable electrode. J. Cardiovasc. Electrophysiol. (1997) 8 1031 1045.
105. Sharma V., Qu F., Nikolski V.P., DeGroot P., Efimov I.R. Direct measurements of membrane time constant during defibrillation strength shocks. Heart Rhythm (2007) 4 478 486.
106. Shorofsky S., Rashba E., DeGroot P., Havel W., Mugglin A., Gold M. Is the membrane time constant for defibrillation independent of the waveform? Pacing Clin. Electrophysiol. (2002) 24 620 abstract.
107. Denman R.A., Umesan C., Martin P.T. et al. Benefit of millisecond waveform durations for patients with high defibrillation thresholds. Heart Rhythm (2006) 3 536 541.
108. Keane D., Aweh N., Hynes B. et al. Achieving sufficient safety margins with fixed duration waveforms and the use of multiple time constants. Pacing Clin. Electrophysiol. (2007) 30 596 602.
109. Mouchawar G., Kroll M., Val-Mejias J.E. et al. ICD waveform optimization: a randomized, prospective, pair-sampled multicenter study. Pacing Clin. Electrophysiol. (2000) 23 (11 Pt 2) 1992 1995.
110. Natarajan S., Henthorn R., Burroughs J. et al. Fixed duration "tuned" defibrillation waveforms outperform fixed 50/50% tilt defibrillation waveforms: a randomized, prospective, pair-sampled multicenter study. Pacing Clin. Electrophysiol. (2007) 30 S139 S142.
111. Val-Mejias J., Doshi S., Kroll M., Oza A.S.S. Is the time constant of the cardiac cell membrane affected by progression of heart disease? Heart Rhythm (2009) Abstract.
112. Gold M.R., Foster A.H., Shorofsky S.R. Lead system optimization for transvenous defibrillation. Am. J. Cardiol. (1997) 80 1163 1167.
113. Gold M.R., Olsovsky M.R., Pelini M.A., Peters R.W., Shorofsky S.R. Comparison of single- and dual-coil active pectoral defibrillation lead systems. J. Am. Coll. Cardiol. (1998) 31 1391 1394.
114. Gold M.R., Olsovsky M.R., DeGroot P.J., Cuello C., Shorofsky S.R. Optimization of transvenous coil position for active can defibrillation thresholds. J. Cardiovasc. Electrophysiol. (2000) 11 25 29.
115. Gold M., Val-Mejias J., Leman R.B. et al. Optimization of superior vena cava coil position and usage for transvenous defibrillation. Heart Rhythm (2008) 5 394 399.
116. Block M., Hammel D., Bocker D., Isbruch F., Wietholt D., Breithardt G. Subcutaneous array lead for internal defibrillation. Pacing Clin. Electrophysiol. (1993) 16 896 Abstract.
117. Higgins S.L., Alexander D.C., Kuypers C.J., Brewster S.A. The subcutaneous array: a new lead adjunct for the transvenous ICD to lower defibrillation thresholds. Pacing Clin. Electrophysiol. (1995) 18 1540 1548.
118. Jordaens L., Vertongen P., van Belleghem Y. A subcutaneous lead array for implantable cardioverter defibrillators. Pacing Clin. Electrophysiol. (1993) 16 (7 Pt 1) 1429 1433.
119. Kettering K., Mewis C., Dornberger V. et al. Long-term experience with subcutaneous ICD leads: a comparison among three different types of subcutaneous leads. Pacing Clin. Electrophysiol. (2004) 27 1355 1361.
120. Kuhlkamp V., Dornberger V., Khalighi K. et al. Effect of a single element subcutaneous array electrode added to a transvenous electrode configuration on the defibrillation field and the defibrillation threshold. Pacing Clin. Electrophysiol. (1998) 21 2596 2605.
121. Kuhlkamp V., Dornberger V., Mewis C., Seipel L. Comparison of the efficacy of a subcutaneous array electrode with a subcutaneous patch electrode, a prospective randomized study. Int. J. Cardiol. (2001) 78 247 256.
122. Cesario D., Bhargava M., Valderrabano M., Fonarow G.C., Wilkoff B., Shivkumar K. Azygos vein lead implantation: a novel adjunctive technique for implantable cardioverter defibrillator placement. J. Cardiovasc. Electrophysiol. (2004) 15 780 783.
123. Cooper J.A., Latacha M.P., Soto G.E. et al. The azygos defibrillator lead for elevated defibrillation thresholds: implant technique, lead stability, and patient series. Pacing Clin. Electrophysiol. (2008) 31 1405 1410.
124. Cooper J.A., Kroll M., Latacha M. et al. Shock Impedance After Replacing the Superior Vena Cava Coil With an Azygos Defibrillation Lead: Implications for Mechanism of Improved Defibrillation Efficacy. Heart Rhythm (2009) abstract.
125. Mitchell C., Hongo R., Belheiry S., Hao S. Right sided placement of defibrillating coil in azygos vein for management of high defibrillation thresholds. Heart Rhythm (2007) abstract.
126. Avitall B., Hare J., Zander G. et al. Cardioversion, defibrillation, and overdrive pacing of ventricular arrhythmias: the effect of moricizine in dogs with sustained monomorphic ventricular tachycardia. Pacing Clin. Electrophysiol. (1993) 16 2092 2097.
127. Pharand C., Goldman R., Fan C., Chow M., Kluger J. Effect of chronic oral moricizine and intravenous epinephrine on ventricular fibrillation and defibrillation thresholds. Pacing Clin. Electrophysiol. (1996) 19 82 89.
128. Ujhelyi M.R., O'Rangers E.A., Kluger J., Fan C., Chow M. Defibrillation energy requirements during moricizine and moricizine-lidocaine therapy. J. Cardiovasc. Pharmacol. (1992) 20 932 939.
129. Jones D.L., Kim Y.H., Natale A., Klein G.J., Varin F. Bretylium decreases and verapamil increases defibrillation threshold in pigs. Pacing Clin. Electrophysiol. (1994) 17 1380 1390.
130. Keelan E.T., Sra J.S., Axtell K. et al. The effect of polarity of the initial phase of a biphasic shock waveform on the defibrillation threshold of pectorally implanted defibrillators. Pacing Clin. Electrophysiol. (1997) 20 (2 Pt 1) 337 342.
131. Narasimhan C., Panotopoulos P.T., Deshpande S. et al. Reversing the initial phase polarity in biphasic shocks: is the polarity benefit reproducible? Pacing Clin. Electrophysiol. (1999) 22 (1 Pt 1) 60 64.
132. Natale A., Sra J., Dhala A. et al. Effects of initial polarity on defibrillation threshold with biphasic pulses. Pacing Clin. Electrophysiol. (1995) 18 1889 1893.
133. Neuzner J., Pitschner H.F., Schwarz T., Dursch M., Schlepper M. Effects of electrode polarity on defibrillation thresholds in biphasic endocardial defibrillation. Am. J. Cardiol. (1996) 78 96 97.
134. Olsovsky M.R., Shorofsky S.R., Gold M.R. Effect of shock polarity on biphasic defibrillation thresholds using an active pectoral lead system. J. Cardiovasc. Electrophysiol. (1998) 9 350 354.
135. Schauerte P., Stellbrink C., Schondube F.A. et al. Polarity reversal improves defibrillation efficacy in patients undergoing transvenous cardioverter defibrillator implantation with biphasic shocks. Pacing Clin. Electrophysiol. (1997) 20 (2 Pt 1) 301 306.
136. Shorofsky S.R., Gold M.R. Effects of waveform and polarity on defibrillation thresholds in humans using a transvenous lead system. Am. J. Cardiol. (1996) 78 313 316.
137. Strickberger S.A., Man K.C., Daoud E. et al. Effect of first-phase polarity of biphasic shocks on defibrillation threshold with a single transvenous lead system. J. Am. Coll. Cardiol. (1995) 25 1605 1608.